Your session is about to expire
← Back to Search
Florbetapir PET/MR scan for Amyloidosis
Phase 1 & 2
Waitlist Available
Led By Stephen M. Broski, M.D.
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 50-120 minutes post injection
Awards & highlights
No Placebo-Only Group
Summary
This trial will test how well PET/MR works in diagnosing amyloidosis in patients with peripheral nerve damage.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 50-120 minutes post injection
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~50-120 minutes post injection
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Locations of peripheral nerve 18-F Florbetapir uptake
Pattern of F-18 Florbetapir uptake (Heterogeneous vs. Homogeneous, focal vs. diffuse)
Secondary study objectives
Additional sites of 18-F Florbetapir uptake
Morphologic changes
Pattern of contrast enhancement (Solid, heterogeneous or peripheral enhancement)
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Peripheral nerve amyloidosisExperimental Treatment1 Intervention
Patients with pathologically-confirmed peripheral nerve amyloidosis will undergo 18-F Florbetapir PET/MR scan on a GE SIGNA PET/MR scanner.
Find a Location
Who is running the clinical trial?
Mayo ClinicLead Sponsor
3,308 Previous Clinical Trials
2,962,421 Total Patients Enrolled
15 Trials studying Amyloidosis
21,703 Patients Enrolled for Amyloidosis
Stephen M. Broski, M.D.Principal InvestigatorMayo Clinic
1 Previous Clinical Trials
24 Total Patients Enrolled
Stephen M BroskiPrincipal InvestigatorMayo Clinic
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You are between 18 and 100 years old.You have metal devices in your body that are not safe for MRI scans, like pacemakers or stents.You are afraid of being in small, enclosed spaces.Your body mass index (BMI) is higher than 38.You have a confirmed condition called peripheral nerve amyloidosis or other confirmed causes of peripheral neuropathy.
Research Study Groups:
This trial has the following groups:- Group 1: Peripheral nerve amyloidosis
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger